Effects of alcaftadine ophthalmic: A Synthesis of Findings from 12 Studies

  1. Home
  2. Effects of alcaftadine ophthalmic
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of alcaftadine ophthalmic: A Synthesis of Findings from 12 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of alcaftadine ophthalmic: A Synthesis of Findings from 12 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Alcaftadine is a topical antihistamine used to treat allergic conjunctivitis. 8 Several studies have found that alcaftadine is more effective than placebo and at least as effective as olopatadine 0.01% in preventing ocular itching at 15 minutes and at 16 hours after administration. 8 , 7 Alcaftadine is a broad-spectrum antihistamine that displays a high affinity for histamine H1 and H2 receptors and a lower affinity for H4 receptors. 8 It also exhibits modulatory action on immune cell recruitment and mast cell stabilizing effects. 8 Alcaftadine 0.025% ophthalmic solution has been approved by the U.S. Food and Drug Administration for prevention of itching associated with allergic conjunctivitis in patients over 2 years of age. 8 Alcaftadine has shown promise in suppressing the excretory-secretory protein of Acanthamoeba, a potential trigger for allergic conjunctivitis. 1 Additionally, alcaftadine has demonstrated less cytotoxicity and stronger anti-allergic effects compared to other topical antihistamines and mast cell stabilizers. 3 Alcaftadine has shown to be effective in relieving itching, redness, swelling, and tearing, common symptoms of ocular allergies. 6 However, it is important to note that alcaftadine can potentially cause allergic contact dermatitis. 4

Benefits and risks

Benefits summary

Alcaftadine eye drops may effectively reduce symptoms of allergic conjunctivitis, especially itching. 8 , 7 , 5 , 2 Alcaftadine has demonstrated less cytotoxicity and stronger anti-allergic effects compared to other topical antihistamines and mast cell stabilizers. 3 Furthermore, alcaftadine has shown promise in suppressing the excretory-secretory protein of Acanthamoeba, a potential trigger for allergic conjunctivitis. 1

Risks summary

Alcaftadine eye drops are generally safe and well-tolerated, but some patients may experience side effects like eye irritation, burning, and redness. , 2 Rarely, serious side effects like allergic contact dermatitis can occur. 4

Comparison between studies

Commonalities between studies

Multiple studies have confirmed that alcaftadine is more effective than placebo and at least as effective as olopatadine 0.01% in reducing eye itching. 8 , 7 These studies support the conclusion that alcaftadine is an effective treatment for allergic conjunctivitis. 6

Differences between studies

There is some variability in the data on the efficacy and safety of alcaftadine across studies. 7 This may be due to differences in study design, participants, the concentration of alcaftadine used, and the cause of allergic conjunctivitis. 5

Consistency and contradictions of the results

Alcaftadine eye drops have shown to reduce symptoms of allergic conjunctivitis but some patients may experience side effects like eye irritation, burning, and redness. , 2 Rarely, serious side effects like allergic contact dermatitis can occur. 4 Further research is required to address these contradictory results. 10

Notes on real-life application

Alcaftadine eye drops can be helpful for treating allergic conjunctivitis, but it’s important to consult a doctor before using them. Your doctor can determine the best treatment plan based on your individual needs. 6 If you experience any side effects while using alcaftadine eye drops, consult your doctor immediately. 4

Limitations of current research

There is still a lack of sufficient research evaluating the efficacy and safety of alcaftadine. 11 In particular, data on the long-term effects and safety of alcaftadine is limited. 10 While alcaftadine has demonstrated less cytotoxicity and stronger anti-allergic effects compared to other topical antihistamines and mast cell stabilizers, these studies involved limited participants. 3

Future research directions

Research is needed to evaluate the long-term efficacy and safety of alcaftadine. 11 Comparative studies with other topical antihistamines and mast cell stabilizers are also warranted. 3 Additionally, research aimed at elucidating the mechanisms of action of alcaftadine is crucial. 10

Conclusion

Alcaftadine has shown promise as a treatment for allergic conjunctivitis. 8 , 6 However, there is a potential for side effects in some patients. If you are considering using alcaftadine eye drops, consult your doctor for advice. 4

Literature analysis of 12 papers
Positive Content
11
Neutral Content
0
Negative Content
1
Article Type
5
0
0
3
12
1.

Development of allergic conjunctivitis induced by <i>Acanthamoeba</i> excretory-secretory protein and the effect of resolvin D1 on treatment.

Author: KangMin Seung, LeeJongsoo, ParkSung Hee, YuHak Sun, LeeJi-Eun

Reduced AC symptoms
None mentioned

This study found that exposure to dust mite allergen (ESP) induced allergic conjunctivitis in both human conjunctival epithelial cells and mice. Treatment with resolvin D1 (RvD1) and antiallergic agents significantly reduced the inflammation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Efficacy of Alcaftadine 0.25% (AGN-229666) for Once-daily Prevention of Cedar-Pollen Allergic Conjunctivitis: A Phase 3 Randomized Study.

Author: FujishimaHiroshi, HasunumaTomoko, KawakitaTetsuya, SekiyaTakuro, GomesPaul, HollanderDavid A

allergic conjunctivitis treatment
minimal side effects

Once-daily Alcaftadine 0.25% is effective and safe for preventing signs and symptoms of Japanese cedar-pollen allergic conjunctivitis. This study found that Alcaftadine 0.25% was superior to vehicle for relief of ocular itching and conjunctival hyperemia at 16 hours and was non-inferior to olopatadine at 4 hours.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

3.

Comparison of cytotoxicities and anti-allergic effects of topical ocular dual-action anti-allergic agents.

Author: KimSung Il, ParkChoul Yong, FordjuorGladys, LeeJong Heon, LeeJong Soo, LeeJi Eun

Alcaftadine
Anti-allergic effects
Ocular surface health
Ocular toxicity

This study found that alcaftadine, a topical ocular dual-action anti-allergic agent, showed the least cytotoxicity and best therapeutic effects compared to bepotastine besilate and olopatadine HCL.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report.

Author: KimJae Hyuk, KimHyun Joon, KimSun Woong

Allergic contact dermatitis

Alcaftadine 0.25% ophthalmic solution should be suspected as a cause of allergic contact dermatitis (ACD) in patients with swelling and erythema of both eyes after using the medication.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

5.

Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study.

Author: NakataniHiroshi, GomesPaul, BradfordRon, GuoQiang, SafyanEleonora, HollanderDavid A

Allergic conjunctivitis prevention

This study compared the efficacy and safety of alcaftadine and olopatadine ophthalmic solutions for preventing allergen-mediated conjunctivitis in Japanese subjects. Alcaftadine 0.25% was more effective than vehicle and noninferior to olopatadine 0.1% in preventing itching and conjunctival hyperemia. Both drugs were well tolerated.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

6.

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis.

Author: ChigbuDeGaulle I, CoyneAlissa M

Allergic conjunctivitis treatment

Alcaftadine is an effective treatment for allergic conjunctivitis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

7.

Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials.

Author: McLaurinEugene B, MarsicoNicholas P, AckermanStacey L, CiolinoJoseph B, WilliamsJulia M, VillanuevaLinda, HollanderDavid A

Ocular itching prevention

Once-daily alcaftadine 0.25% ophthalmic solution demonstrated greater efficacy in prevention of ocular itching compared with olopatadine 0.2% at 3 min post-CAC (primary endpoint), and over all time points, 16 h post-treatment instillation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Alcaftadine: a topical antihistamine for use in allergic conjunctivitis.

Author: NamdarR, ValdezC

Treats allergic conjunctivitis

This review summarizes the efficacy, safety, and pharmacokinetic profile of alcaftadine ophthalmic solution, a broad-spectrum antihistamine. Alcaftadine is effective in preventing ocular itching associated with allergic conjunctivitis and has been approved by the U.S. Food and Drug Administration for use in patients over 2 years of age.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

Histamine and H1-antihistamines: celebrating a century of progress.

Author: SimonsF Estelle R, SimonsKeith J

H1-antihistamine efficacy
H1-antihistamine safety

This review discusses the history and progress of antihistamines, highlighting their clinical pharmacology, efficacy, and safety.

Historical ArticleA research paper that analyzes past events and developments using primary sources and examines them from a historical perspective.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis.

Author: OnoSanta J, LaneKeith

Allergic conjunctivitis
Ocular allergy

This study compared the effects of two antihistamines, olopatadine and alcaftadine, on epithelial cell changes associated with allergic conjunctivitis. The results suggest that both antihistamines effectively modified these changes, particularly at time points reflecting late-phase reactions.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

Clinical pharmacology of alcaftadine, a novel antihistamine for the prevention of allergic conjunctivitis.

Author: BohetsHilde, McGowanClaude, MannensGeert, SchroederNathalie, Edwards-SwansonKimberly, ShapiroAron

Ocular Allergic Treatment

Alcaftadine is a new antihistamine that has been shown to be effective for the treatment and prevention of allergic conjunctivitis. A study of healthy subjects found that alcaftadine was well tolerated and had an acceptable safety profile.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

12.

The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis.

Author: TorkildsenGail, SheddenArthur

Allergy symptom reduction
Itching prevention
Redness reduction

Alcaftadine 0.25% ophthalmic solution is effective in preventing ocular itching and redness in patients with allergic conjunctivitis.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.